Commentary on the "Co-Crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-Surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre Phase II Trial". Implications for Cardiovascular Safety
{"title":"Commentary on the \"Co-Crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-Surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre Phase II Trial\". Implications for Cardiovascular Safety","authors":"S. Videla, Neus Gascón, C. Plata-Salamán","doi":"10.29245/2578-3025/2018/1.1163","DOIUrl":null,"url":null,"abstract":"Page 1 of 3 Commentary on the “Co-Crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-Surgical Oral Pain: A DoseFinding, Randomised, Double-Blind, Placeboand Active-Controlled, Multicentre Phase II Trial”. Implications for Cardiovascular Safety Sebastián Videla1*, Neus Gascón2, Carlos Plata-Salamán2 1Clinical Research Support Unit, Clinical Pharmacology Department, Bellvitge University Hospital/IDIBELL, Barcelona, Spain. 2Medical Sciences Area, ESTEVE Pharmaceuticals S.A., Barcelona, Spain.","PeriodicalId":93019,"journal":{"name":"Journal of cardiology and cardiovascular sciences","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cardiology and cardiovascular sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29245/2578-3025/2018/1.1163","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Page 1 of 3 Commentary on the “Co-Crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-Surgical Oral Pain: A DoseFinding, Randomised, Double-Blind, Placeboand Active-Controlled, Multicentre Phase II Trial”. Implications for Cardiovascular Safety Sebastián Videla1*, Neus Gascón2, Carlos Plata-Salamán2 1Clinical Research Support Unit, Clinical Pharmacology Department, Bellvitge University Hospital/IDIBELL, Barcelona, Spain. 2Medical Sciences Area, ESTEVE Pharmaceuticals S.A., Barcelona, Spain.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
